Literature DB >> 24798166

Nationwide prevalence of lymph node metastases in Gleason score 3 + 3 = 6 prostate cancer.

Jen-Jane Liu1, Daphne Y Lichtensztajn, Scarlett Lin Gomez, Weiva Sieh, Benjamin I Chung, Iona Cheng, James D Brooks.   

Abstract

Based on revisions of Gleason scoring in 2005, it has been reported that nodal metastases at radical prostatectomy in Gleason 3 + 3 = 6 (GS6) prostate cancer are extremely rare, and that GS6 cancers with nodal metastases are invariably upgraded upon review by academic urological pathologists. We analysed the prevalence and determinants of nodal metastases in a national sample of patients with GS6 cancer.We utilised the SEER database to identify patients diagnosed with GS6 prostate cancer during 2004-2010 who had radical prostatectomy and ≥1 lymph node(s) examined. We calculated the prevalence of nodal metastases and constructed a multivariable logistic regression model to identify factors associated with nodal metastases. Among 21,960 patients, the prevalence of nodal metastases was 0.48%. Older age, preoperative PSA >10  ng/mL, and advanced stage were positively associated with nodal metastases. Lymph node metastases in GS6 cancer are more prevalent in a nationwide population compared to academic centres. Revised guidelines for Gleason scoring have made GS6 cancer a more homogeneously indolent disease, which may be relevant in the era of active surveillance. We submit that lymph node metastases in GS6 cancer be used as a proxy for adherence to the 2005 ISUP consensus on Gleason grading.

Entities:  

Mesh:

Year:  2014        PMID: 24798166      PMCID: PMC5746183          DOI: 10.1097/PAT.0000000000000097

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  17 in total

Review 1.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

2.  Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

Authors:  Hillary M Ross; Oleksandr N Kryvenko; Janet E Cowan; Jeffry P Simko; Thomas M Wheeler; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2012-09       Impact factor: 6.394

3.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

4.  Prostate cancer and the Will Rogers phenomenon.

Authors:  Peter C Albertsen; James A Hanley; George H Barrows; David F Penson; Pam D H Kowalczyk; M Melinda Sanders; Judith Fine
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

5.  Classification of prostatic carcinomas.

Authors:  D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

6.  Survival rates of patients with prostatic cancer, tumor stage, and differentiation--preliminary report.

Authors:  J C Bailar; G T Mellinger; D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

7.  Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade.

Authors:  Christopher R King; John E McNeal; Harcharan Gill; James D Brooks; Sandy Srinivas; Joseph C Presti
Journal:  Urology       Date:  2006-06       Impact factor: 2.649

8.  Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.

Authors:  H Ballentine Carter; Patrick C Walsh; Patricia Landis; Jonathan I Epstein
Journal:  J Urol       Date:  2002-03       Impact factor: 7.450

9.  NIH State-of-the-Science Conference Statement: Role of active surveillance in the management of men with localized prostate cancer.

Authors:  Patricia A Ganz; John M Barry; Wylie Burke; Nananda F Col; Phaedra S Corso; Everett Dodson; M Elizabeth Hammond; Barry A Kogan; Charles F Lynch; Lee Newcomer; Eric J Seifter; Janet A Tooze; Kasisomayajula Vish Viswanath; Hunter Wessells
Journal:  NIH Consens State Sci Statements       Date:  2011 Dec 5-7

10.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Authors:  Laurence Klotz; Liying Zhang; Adam Lam; Robert Nam; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

View more
  8 in total

Review 1.  Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.

Authors:  Alessandro Conti; Matteo Santoni; Luciano Burattini; Marina Scarpelli; Roberta Mazzucchelli; Andrea B Galosi; Liang Cheng; Antonio Lopez-Beltran; Alberto Briganti; Francesco Montorsi; Rodolfo Montironi
Journal:  World J Urol       Date:  2015-12-22       Impact factor: 4.226

2.  Low-Risk Prostate Cancer and Tumor Upgrading in the Surgical Specimen: Analysis of Clinical Factors Predicting Tumor Upgrading in a Contemporary Series of Patients Who were Evaluated According to the Modified Gleason Score Grading System.

Authors:  Antonio B Porcaro; Salvatore Siracusano; Nicolò de Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Daniele Mattevi; Leonardo Bizzotto; Irene Tamanini; Maria A Cerruto; Guido Martignoni; Matteo Brunelli; Walter Artibani
Journal:  Curr Urol       Date:  2017-07-30

Review 3.  Does true Gleason pattern 3 merit its cancer descriptor?

Authors:  Saiful Miah; Hashim U Ahmed; Alex Freeman; Mark Emberton
Journal:  Nat Rev Urol       Date:  2016-08-17       Impact factor: 14.432

4.  Active surveillance for the management of localized prostate cancer: Guideline recommendations.

Authors:  Chris Morash; Rovena Tey; Chika Agbassi; Laurence Klotz; Tom McGowan; John Srigley; Andrew Evans
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

Review 5.  Cancer overdiagnosis: a biological challenge and clinical dilemma.

Authors:  Sudhir Srivastava; Eugene J Koay; Alexander D Borowsky; Angelo M De Marzo; Sharmistha Ghosh; Paul D Wagner; Barnett S Kramer
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

Review 6.  Should Gleason 6 be labeled as cancer?

Authors:  Ibrahim Kulac; Michael C Haffner; Srinivasan Yegnasubramanian; Jonathan I Epstein; Angelo M De Marzo
Journal:  Curr Opin Urol       Date:  2015-05       Impact factor: 2.309

Review 7.  Extracellular vesicles in prostate cancer: a narrative review.

Authors:  Koji Hatano; Kazutoshi Fujita
Journal:  Transl Androl Urol       Date:  2021-04

8.  Hemiablative Focal Low Dose Rate Brachytherapy: A Phase II Trial Protocol.

Authors:  Ana Fernandez Ots; Joseph Bucci; Yaw Sinn Chin; David Malouf; Andrew Howie; Komiti Ese Enari
Journal:  JMIR Res Protoc       Date:  2016-06-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.